Premium
Survival rates of biological therapies for psoriasis treatment in real‐world clinical practice: A Canadian multicentre retrospective study
Author(s) -
Marinas Joseph EC,
Kim Whan B,
Shahbaz Ali,
Qiang Judy K,
Greaves Simon,
Yeung Jensen
Publication year - 2018
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.12548
Subject(s) - medicine , ustekinumab , etanercept , adalimumab , infliximab , psoriasis , log rank test , survival analysis , retrospective cohort study , hazard ratio , clinical trial , dermatology , disease , confidence interval , rheumatoid arthritis
Background/Objectives Data on biologic drug survival in real‐world psoriasis treatment are limited. There is a need to evaluate long‐term trends of biologic use outside the realm of clinical trials. Methods A multicentre chart review was conducted with patients' data from September 2005 to September 2014. Kaplan–Meier plot analysis was used to determine 5‐year drug survival rates. A log–rank test was used to compare the rates of drug survival between the studied biologics. Results For the 398 patients and 545 treatment series analysed, 1, 2, 3, 4 and 5‐year survival rates were 0.826, 0.687, 0.563, 0.475 and 0.420 with etanercept; 0.804, 0.648, 0.553, 0.508 and 0.508 with adalimumab; 0.838, 0.664, 0.554, 0.485 and 0.382 with infliximab; and 0.914, 0.856, 0.800, 0.755 and 0.755 with ustekinumab, respectively. A statistically significant difference was seen between ustekinumab and the other three biologics. Conclusion A progressive decrease in treatment adherence was seen with all four biologics, as expected, but the survival rate of ustekinumab was highest.